Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Gamarra Luques, Carlos D ^a,b   Hapon, Maria B ^a,b   Goyeneche, Alicia A ^a   Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Institute of Medicine and Experimental Biology of Cuyo National Council for Scientific and Technical Research ^*  (Argentina)

Author keywords

Antiprogestins; Chemoresistance; Ovarian cancer

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MIFEPRISTONE; PACLITAXEL; PLATINUM DERIVATIVE; PLATINUM TAXANE ESCAPE DERIVATIVE; TAXANE DERIVATIVE; ULIPRISTAL; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CDB-4453; ESTRANE DERIVATIVE; FURAN DERIVATIVE; HORMONE ANTAGONIST; PREGNANE DERIVATIVE; TELAPRISTONE ACETATE;

ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL DEATH; CELL DIVISION; CELL FATE; CELL GROWTH; CELL VIABILITY; CELLS; CONTROLLED STUDY; CYTOSTASIS; DNA CONTENT; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IGROV 1 CELL; LETHALITY; MICROCIRCULATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; SIBLING; SKOV 3 CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; IC50; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ESTRENES; FEMALE; FURANS; HORMONE ANTAGONISTS; HUMANS; INHIBITORY CONCENTRATION 50; MIFEPRISTONE; NORPREGNADIENES; PACLITAXEL;

EID: 84899896867     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-45     Document Type: Article

References (43)

1. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Romero I, Bast RC Jr, Endocrinology 2012 153 4 1593 1602 10.1210/en.2011-2123 22416079
2. Rethinking ovarian cancer: recommendations for improving outcomes. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR, Nat Rev Cancer 2011 11 10 719 725 10.1038/nrc3144 21941283
3. The biology of ovarian cancer: new opportunities for translation. Bast RC Jr, Hennessy B, Mills GB, Nat Rev Cancer 2009 9 6 415 428 10.1038/nrc2644 19461667
4. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Kurman RJ, Shih Ie M, Hum Pathol 2011 42 7 918 931 10.1016/j.humpath.2011.03.003 21683865
5. Latest research and treatment of advanced-stage epithelial ovarian cancer. Coleman RL, Monk BJ, Sood AK, Herzog TJ, Nat Rev Clin Oncol 2013 10 4 211 224 10.1038/nrclinonc.2013.5 23381004
6. Molecular approaches to personalizing management of ovarian cancer. Bast RC Jr, Ann Oncol 2011 22 Suppl 8 22iii5 22180401
7. Antiprogestins in Ovarian Cancer. Telleria CM, Goyeneche AA, Ovarian Cancer -Clinical and Therapeutic Perspectives Rijeka, Croatia: InTechopen, Farghaly S, Chapter 11 2012
8. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Goyeneche AA, Caron RW, Telleria CM, Clin Cancer Res 2007 13 11 3370 3379 10.1158/1078-0432.CCR-07-0164 17545545
9. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Freeburg EM, Goyeneche AA, Telleria CM, Int J Oncol 2009 34 3 743 755 19212679
10. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM, BMC Cancer 2012 12 200 10.1186/1471-2407-12-200 22642877
11. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Goyeneche AA, Seidel EE, Telleria CM, Invest New Drugs 2012 30 3 967 980 10.1007/s10637-011-9655-z 21424700
12. Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM, Cancer Cell Int 2009 9 4 10.1186/1475-2867-9-4 19222856
13. Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer. Kurata T, Tamura T, Shinkai T, Ohe Y, Kunitoh H, Kodama T, Kakinuma R, Matsumoto T, Kubota K, Omatsu H, Nishiwaki Y, Saijo N, Jpn J Clin Oncol 2001 31 3 93 99 10.1093/jjco/hye022 11336328
14. Clinical kinetics on intact cisplatin and some related species. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA, Clin Pharmacol Ther 1981 29 5 658 664 10.1038/clpt.1981.91 7194166
15. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. du Bois A, Luck HJ, Buser K, Meerpohl HG, Sessa C, Klaassen U, Meden H, Bochtler H, Diergarten K, Eur J Cancer 1997 33 3 379 384 10.1016/S0959-8049(97)89009-0 9155520
16. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC, Smyth JF, Cancer Res 1988 48 21 6166 6172 3167863
17. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD, Oncogene 2010 29 35 4905 4913 10.1038/onc.2010.245 20581869
18. cis- Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR, Cancer Chemother Pharmacol 1996 37 5 463 471 10.1007/s002800050413 8599870
19. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. MdDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O'Donovan N, Stordal B, Frontiers Oncol 2014 4 40
20. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB, Cancer Res 2002 62 22 6559 6565 12438251
21. Optimal treatment for relapsing ovarian cancer. Ledermann JA, Kristeleit RS, Ann Oncol 2010 21 Suppl 7 22ii218 vii222 20943618
22. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. Stordal B, Hamon M, McEneaney V, Roche S, Gillet JP, O'Leary JJ, Gottesman M, Clynes M, PLoS One 2012 7 7 40717 10.1371/journal.pone.0040717 22792399
23. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Yan XD, Li M, Yuan Y, Mao N, Pan LY, Oncol Rep 2007 17 5 1163 1169 17390060
24. The impact of p53 status on cellular sensitivity to antifolate drugs. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR, Clin Cancer Res 2001 7 7 2114 2123 11448931
25. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Siddik ZH, Mims B, Lozano G, Thai G, Cancer Res 1998 58 4 698 703 9485023
26. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M, Cancer Res 1997 57 5 870 874 9041188
27. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection. Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F, Cell Growth Differ 1999 10 7 473 478 10437915
28. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Yaginuma Y, Westphal H, Cancer Res 1992 52 15 4196 4199 1638534
29. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW, Cancer Res 1997 57 19 4285 4300 9331090
30. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T, Cancer Biol Ther 2008 7 5 699 708 10.4161/cbt.7.5.5712 18277095
31. The UMD TP53 database and website: update and revisions. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T, Hum Mutat 2006 27 1 14 20 10.1002/humu.20269 16278824
32. Regio and stereospecific synthesis of 11 beta- substituted 19-norsteroids. Influence of 11 beta-substitution on progesterone receptor affinity-(1). Belanger A, Philibert D, Teutsch G, Steroids 1981 37 4 361 382 10.1016/0039-128X(81)90039-8 7245285
33. Selective progesterone receptor modulators 1: use during pregnancy. Benagiano G, Bastianelli C, Farris M, Expert Opin Pharmacother 2008 9 14 2459 2472 10.1517/14656566.9.14.2459 18778184
34. Investigational developments for the treatment of progesterone-dependent diseases. Moller C, Hoffmann J, Kirkland TA, Schwede W, Expert Opin Investig Drugs 2008 17 4 469 479 10.1517/13543784.17.4.469 18363513
35. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP, Mol Cell Endocrinol 2002 188 1-2 111 123 11911951
36. Mechanism of action of progesterone antagonists. Leonhardt SA, Edwards DP, Exp Biol Med (Maywood) 2002 227 11 969 980 12486206
37. Drug Repurposing for Cancer Therapy. Telleria CM, J Cancer Sci Ther 2012 4 7 x xi 22984635
38. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Spitz IM, Curr Opin Obstet Gynecol 2009 21 4 318 324 10.1097/GCO.0b013e32832e07e8 19602929
39. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. Attardi BJ, Burgenson J, Hild SA, Reel JR, J Steroid Biochem Mol Biol 2004 88 3 277 288 10.1016/j.jsbmb.2003.12.004 15120421
40. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non- reproductive origin regardless of progesterone receptor expression. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM, BMC Cancer 2011 11 207 10.1186/1471-2407-11-207 21619605
41. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV, Int J Oncol 2003 23 2 369 380 12851686
42. Glucocorticoid receptor signaling in health and disease. Kadmiel M, Cidlowski JA, Trends Pharmacol Sci 2013 34 9 518 530 10.1016/j.tips.2013.07.003 23953592
43. Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA, Mol Cell Biol 2007 27 6 2266 2282 10.1128/MCB.01439-06 17242213